Skip to Content

BioCardia Inc BCDA

Morningstar Rating
$0.36 −0.02 (4.51%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BCDA is trading at a 57% discount.
Price
$0.36
Fair Value
$9.79
Uncertainty
Extreme
1-Star Price
$29.57
5-Star Price
$3.66
Economic Moat
Ssh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCDA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.38
Day Range
$0.360.37
52-Week Range
$0.362.92
Bid/Ask
$0.35 / $0.38
Market Cap
$9.67 Mil
Volume/Avg
97,291 / 397,579

Key Statistics

Price/Earnings (Normalized)
Price/Sales
16.74
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP® autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an “off the shelf” cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO™), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
20

Comparables

Valuation

Metric
BCDA
CBAY
OBIO
Price/Earnings (Normalized)
Price/Book Value
12.652.48
Price/Sales
16.74111.0156.70
Price/Cash Flow
Price/Earnings
BCDA
CBAY
OBIO

Financial Strength

Metric
BCDA
CBAY
OBIO
Quick Ratio
0.3210.707.82
Current Ratio
0.4010.967.95
Interest Coverage
−5.27
Quick Ratio
BCDA
CBAY
OBIO

Profitability

Metric
BCDA
CBAY
OBIO
Return on Assets (Normalized)
−169.92%−30.06%−35.16%
Return on Equity (Normalized)
−828.20%−51.97%−51.40%
Return on Invested Capital (Normalized)
−377.00%−30.87%−50.12%
Return on Assets
BCDA
CBAY
OBIO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLljcnnqmflXqmb$550.4 Bil
VRTX
Vertex Pharmaceuticals IncSnhbyjblQnkftg$101.7 Bil
REGN
Regeneron Pharmaceuticals IncKswscbzBnrqkqp$98.1 Bil
MRNA
Moderna IncLwbnlwdwHnpy$38.8 Bil
ARGX
argenx SE ADRSvstqzmsCtj$21.7 Bil
BNTX
BioNTech SE ADRPxndwccdFhjq$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncJvllwmfgNrkzxz$18.4 Bil
BMRN
Biomarin Pharmaceutical IncLwnwkxxyKksjvsz$17.1 Bil
RPRX
Royalty Pharma PLC Class AMzllyhllrtPkymv$12.5 Bil
INCY
Incyte CorpQrjhrmnxdPvvhzpp$11.9 Bil

Sponsor Center